https://www.thehindubusinessline.com/portfolio/commodity-analysis/f-o-strategy-buy-dr-lal-path-labs-call-option/article66846156.ece Copy The stock of Dr Lal Path Labs ...

Om Manchanda, managing director of Lal PathLabs, is moving on to an advisory role after steering the company for close to two decades Bonanza Portfolio’s Omkar Kamtekar recommended investors buy into ...

Explore DR LAL PATH LABS F stock price history with detailed daily historical prices, including open, high, low, and volume data. Review stock chart history to analyze past trends and find the highest ...

Diagnostic services provider Dr Lal PathLabs's (LPL's) board on Tuesday approved 100% acquisition of Suburban Diagnostics (India) in an all-cash deal for an enterprise value of Rs 925 crore. Suburban ...

April 25 (Reuters) - Dr Lal Path Labs (DLPA.NS), opens new tab, India's largest diagnostics firm by revenue, reported fourth-quarter profit above expectations on Friday as strong demand for its ...

Shares of medical diagnostics firm Dr Lal PathLabs plunged around 8 per cent in Wednesday's trade after the company's September quarter results missed estimates on account of higher expenses. The ...

Dr Lal Path Labs delivered a beat on margins at 28.2 per cent. However, revenue was in-line while EBITDA/PAT delivered a slight beat by 4/5 per cent respectively. Overall revenue increased 11 per cent ...

India's Dr Lal Path Labs beats quarterly profit view on medical testing boom Dr Lal Path Labs , India's largest diagnostics firm by revenue, reported fourth-quarter profit above expectations on Friday ...

Delhi-based Dr Lal PathLabs is an international service provider of diagnostic and related healthcare tests. With more than 2500 collection centres and 200 labs, Dr Lal PathLabs serves 70 thousand ...

Dr Lal PathLabs’ shares sank over four percent intraday on Monday, April 28. While the medical diagnostic centre reported a steady March quarter, brokerages had a mixed outlook for the current quarter ...